A 344-amino-acid glycoprotein that binds and neutralizes myostatin, activin, and other TGF-beta superfamily members. By blocking myostatin (the body's natural muscle growth limiter), follistatin promotes significant muscle hypertrophy. One of the most potent muscle-building biologics studied.
Follistatin (FST-344) is a 344-amino-acid glycoprotein that acts as a natural antagonist of myostatin, activin, and other TGF-beta superfamily ligands. Myostatin is the body's 'muscle growth brake' — it signals muscle cells to stop growing. Follistatin binds myostatin with high affinity, neutralizing it and removing the brake on muscle growth.
Animals and humans with natural follistatin overexpression or myostatin loss-of-function mutations display dramatic muscle hypertrophy — the 'double-muscled' phenotype seen in Belgian Blue cattle and the few documented human cases of myostatin mutations. This genetic proof-of-concept has driven intense interest in follistatin as a potential treatment for muscle wasting diseases.
Follistatin neutralizes myostatin through direct high-affinity binding. Myostatin normally binds to the activin type IIB receptor (ActRIIB), activating the Smad2/3 signaling cascade that represses muscle growth gene expression. When follistatin intercepts myostatin before it reaches the receptor, this repressive signaling is blocked, allowing muscle satellite cells to proliferate and existing muscle fibers to grow.
| Pathway | Effect | Significance |
|---|---|---|
| Myostatin neutralization | High-affinity binding traps myostatin extracellularly | Removes the primary brake on muscle growth |
| Activin inhibition | Also binds activin A, activin B, and GDF-11 | Broader TGF-beta superfamily inhibition beyond myostatin alone |
| Muscle hypertrophy | De-repression of muscle growth gene transcription | Significant increases in muscle mass in animal models |
| Anti-fibrotic | Inhibition of activin/TGF-beta reduces fibrosis | Potential benefit in muscular dystrophy (fibrosis is a major pathological feature) |
| Satellite cell activation | Promotes muscle stem cell proliferation | May enable muscle regeneration, not just hypertrophy |
| Study | Design | Findings | Level |
|---|---|---|---|
| Genetic proof | Human + animal genetics | Myostatin knockout mice have 2-3x normal muscle mass. Rare human myostatin mutations produce extraordinary muscularity. Belgian Blue cattle are double-muscled from myostatin disruption. | Level I (genetic) |
| Gene therapy | Preclinical + Phase I | AAV-follistatin gene therapy in non-human primates produced significant muscle growth. Phase I human trials for Becker muscular dystrophy showed safety and some efficacy. | Level I-II |
| Duchenne MD | Preclinical | Follistatin overexpression improved muscle function in DMD mouse models | Preclinical |
| Sarcopenia | Preclinical | Follistatin administration improved muscle mass and strength in aged mice | Preclinical |
Off-target TGF-beta effects: Follistatin inhibits activins broadly, which play roles in reproductive function, wound healing, and other processes. Systemic administration could have unintended effects.
Reproductive effects: Activin is critical for FSH regulation and fertility. Follistatin overexpression could impair reproductive function.
Not a small peptide: At 344 amino acids, follistatin is a large glycoprotein — more like a biologic drug than a typical peptide. Manufacturing, stability, and delivery are complex.
Theoretical cancer risk: Myostatin/activin signaling can suppress tumor growth in some contexts. Long-term inhibition could theoretically increase certain cancer risks.
| Jurisdiction | Status |
|---|---|
| FDA | Not approved. Investigational for muscular dystrophy gene therapy. |
| WADA | Banned. Myostatin inhibitors and follistatin are specifically listed under S4.5. |
| Research | Most advanced as AAV gene therapy vector. Injectable protein formulations are available as research chemicals but are expensive and require cold storage. |